Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
All edits
Edits on 6 Jan, 2024
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+262 characters)
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
Article
Study summary
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Infobox
Is a
NCT Number
Trial Recruitment Size
660
Trial Sponsor
Clinical Trial Start Date
April 7, 2017
0Primary Completion Date
July 1, 2017
0Study Completion Date
May 6, 2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Official Website
Official Name
A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers0
Last Updated
May 30, 2018
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Find more entities like Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.